HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -46.18 Billion KRW | 29.87% |
| 2022 | -65.84 Billion KRW | -225.21% |
| 2021 | -20.24 Billion KRW | 87.78% |
| 2020 | -165.67 Billion KRW | -446.8% |
| 2019 | 47.77 Billion KRW | 92.91% |
| 2018 | 24.76 Billion KRW | -0.46% |
| 2017 | 24.87 Billion KRW | 519.94% |
| 2016 | 4.01 Billion KRW | -77.99% |
| 2015 | 18.23 Billion KRW | 42.64% |
| 2014 | 12.78 Billion KRW | 5.52% |
| 2013 | 12.11 Billion KRW | 897.62% |
| 2012 | -1.51 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -17.99 Billion KRW | 61.04% |
| 2024 Q2 | 35.08 Billion KRW | 294.99% |
| 2023 Q3 | -40.41 Billion KRW | 65.03% |
| 2023 Q2 | -115.57 Billion KRW | 12.7% |
| 2023 FY | -46.18 Billion KRW | 29.87% |
| 2023 Q1 | -132.37 Billion KRW | -101.03% |
| 2023 Q4 | -46.18 Billion KRW | -14.28% |
| 2022 Q4 | -65.84 Billion KRW | -229.72% |
| 2022 Q3 | 50.76 Billion KRW | 16.35% |
| 2022 Q2 | 43.63 Billion KRW | 96.1% |
| 2022 Q1 | 22.24 Billion KRW | 209.88% |
| 2022 FY | -65.84 Billion KRW | -225.21% |
| 2021 Q4 | -20.24 Billion KRW | 86.15% |
| 2021 Q2 | -140.64 Billion KRW | 13.73% |
| 2021 FY | -20.24 Billion KRW | 87.78% |
| 2021 Q1 | -163.02 Billion KRW | 2.58% |
| 2021 Q3 | -146.18 Billion KRW | -3.94% |
| 2020 Q1 | 46.39 Billion KRW | -0.64% |
| 2020 FY | -165.67 Billion KRW | -446.8% |
| 2020 Q2 | -105.2 Billion KRW | -326.77% |
| 2020 Q3 | -140.44 Billion KRW | -33.5% |
| 2020 Q4 | -167.33 Billion KRW | -19.15% |
| 2019 Q1 | 39.6 Billion KRW | 59.92% |
| 2019 Q2 | 38.52 Billion KRW | -2.73% |
| 2019 FY | 47.77 Billion KRW | 92.91% |
| 2019 Q4 | 46.69 Billion KRW | -2.52% |
| 2019 Q3 | 47.89 Billion KRW | 24.34% |
| 2018 Q1 | 43.17 Billion KRW | 51.36% |
| 2018 Q4 | 24.76 Billion KRW | 329.54% |
| 2018 Q3 | 5.76 Billion KRW | -69.4% |
| 2018 Q2 | 18.83 Billion KRW | -56.36% |
| 2018 FY | 24.76 Billion KRW | -0.46% |
| 2017 Q4 | 28.52 Billion KRW | -5.32% |
| 2017 FY | 24.87 Billion KRW | 519.94% |
| 2017 Q1 | 5.46 Billion KRW | 36.09% |
| 2017 Q2 | 9.22 Billion KRW | 68.83% |
| 2017 Q3 | 30.12 Billion KRW | 226.49% |
| 2016 Q3 | 2.16 Billion KRW | -62.47% |
| 2016 FY | 4.01 Billion KRW | -77.99% |
| 2016 Q4 | 4.01 Billion KRW | 85.48% |
| 2016 Q2 | 5.76 Billion KRW | 6.26% |
| 2016 Q1 | 5.42 Billion KRW | -70.24% |
| 2015 Q1 | 10.7 Billion KRW | -16.26% |
| 2015 Q4 | 18.23 Billion KRW | 229.72% |
| 2015 FY | 18.23 Billion KRW | 42.64% |
| 2015 Q2 | 1.52 Billion KRW | -85.76% |
| 2015 Q3 | 5.53 Billion KRW | 262.79% |
| 2014 Q4 | 12.78 Billion KRW | -19.09% |
| 2014 Q3 | 15.79 Billion KRW | 2.77% |
| 2014 Q2 | 15.37 Billion KRW | 34.64% |
| 2014 Q1 | 11.41 Billion KRW | -5.75% |
| 2014 FY | 12.78 Billion KRW | 5.52% |
| 2013 Q4 | 12.11 Billion KRW | 11.57% |
| 2013 FY | 12.11 Billion KRW | 897.62% |
| 2013 Q1 | 13.73 Billion KRW | 1004.31% |
| 2013 Q3 | 10.85 Billion KRW | -18.33% |
| 2013 Q2 | 13.29 Billion KRW | -3.2% |
| 2012 Q4 | -1.51 Billion KRW | 0.0% |
| 2012 FY | -1.51 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | -13.795% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 201.843% |
| Bioneer Corporation | -3.9 Billion KRW | -1081.828% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 652.976% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 411.748% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 613.61% |
| Helixmith Co., Ltd | -24.42 Billion KRW | -89.076% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 111.874% |
| Medy-Tox Inc. | 49.58 Billion KRW | 193.141% |
| Peptron, Inc. | 4.86 Billion KRW | 1048.59% |
| Amicogen, Inc. | 125.26 Billion KRW | 136.869% |
| Genexine, Inc. | 61.39 Billion KRW | 175.223% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | -237.43% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 17.609% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 186.211% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | -40.211% |
| SillaJen, Inc. | -13.89 Billion KRW | -232.455% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 154.798% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 268.708% |
| Genomictree Inc. | -43.43 Billion KRW | -6.327% |
| MedPacto, Inc. | -64 Billion KRW | 27.839% |
| D&D Pharmatech | -7.5 Billion KRW | -515.138% |
| EASY BIO,Inc. | 53.21 Billion KRW | 186.794% |
| GI Innovation, Inc. | -4.82 Billion KRW | -857.663% |